Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026

Memorial Sloan Kettering Cancer Center Foundations in Immunotherapy in the Oncology Population 2026

Complete Immuno-Oncology Training | CAR T-Cell, Checkpoint Inhibitors & Toxicity Management

📌 Overview

The Memorial Sloan Kettering Cancer Center (MSKCC) Foundations in Immunotherapy 2026 is a comprehensive, evidence-based course designed to provide clinicians with a strong foundation in modern cancer immunotherapy.

This program covers the mechanisms, clinical applications, and toxicity management of immunotherapeutic agents across both solid tumors and hematologic malignancies, with a strong focus on real-world clinical practice.

Developed by experts at one of the world’s leading cancer centers, this course equips healthcare professionals with the knowledge needed to safely and effectively integrate immunotherapy into patient care .

📦 Course Specifications

• Videos: 23 HD lectures
• Subtitles: 23 VTT files
• PDFs: 20 supporting documents
• Total Size: 4.97 GB
• Format: On-demand learning
• Course Date: January 28, 2026

🎯 Target Audience

This course is ideal for:

• Medical oncologists
• Hematologists
• Oncology fellows and residents
• Nurse practitioners and physician assistants in oncology
• Multidisciplinary cancer care teams

🧠 What You Will Learn

🧬 Foundations of Immunotherapy

• Immune system mechanisms in cancer
• Innate vs adaptive immune responses
• Mechanisms of immune checkpoint blockade

💉 Checkpoint Inhibitors & Targeted Therapies

• PD-1, PD-L1, and CTLA-4 inhibitors
• Novel checkpoint inhibitors and combinations
• Clinical applications across multiple cancers

🧫 CAR T-Cell & Cellular Therapy

• CAR T-cell therapy principles and indications
• Patient selection and outcomes
• Toxicities: CRS, ICANS, cytopenias

🔬 Emerging Immunotherapies

• Bispecific antibodies (BiTEs)
• Tumor-infiltrating lymphocytes (TILs)
• Novel immune agonists and IL-2 agents

⚠️ Toxicity & Adverse Event Management

• Immune-related adverse events (irAEs)
• Pneumonitis, dermatologic toxicity, neurotoxicity
• Evidence-based management strategies

🧠 Clinical Application & Case-Based Learning

• Real-world case discussions
• Treatment planning and decision-making
• Personalized immunotherapy approaches

📚 Course Topics Include

• CAR T-cell therapy advancements
• Immunotherapy in leukemia, lymphoma, and myeloma
• Bladder, breast, melanoma, and GI cancers
• Small cell lung cancer immunotherapy
• Dermatologic and pulmonary toxicities
• Neurotoxicity and immune complications
• Bispecific immune-modulating agents
• Checkpoint inhibitor strategies

⚡ Key Benefits

• Master modern immunotherapy principles and applications
• Improve patient selection and treatment outcomes
• Recognize and manage serious immunotherapy toxicities
• Stay updated with latest oncology advances
• Apply knowledge directly in clinical practice

🚀 Why Choose This Course

• Developed by world-leading MSKCC experts
• Covers both foundations and advanced updates
• Focus on practical, real-world oncology care
• Essential for clinicians using or planning immunotherapy

💡 Clinical Value

This course is essential for healthcare professionals who want to:

• Integrate immunotherapy safely into oncology practice
• Improve outcomes in solid and hematologic cancers
• Stay current with rapidly evolving cancer treatments

🏥 About MSKCC

Memorial Sloan Kettering Cancer Center is one of the world’s leading cancer institutions, dedicated to advancing cancer treatment through research, education, and clinical excellence.

4. Topics

1. Advancing CAR T-Cell Strategies and Combination Therapies to Improve Outcomes in Gynecologic Malignancies

2. Advancing Leukemia Care Through Immuno-Oncology

3. Approaches to Immunotherapy-related Pneumonitis Management

4. Breast Oncology- Using cfDNA to Forecast Immunotherapy Treatment Outcomes

5. Checkpoint Inhibition as a Therapeutic Approach in Advanced Hodgkin Lymphoma

6. Clinical Approaches to Dermatologic Toxicity in Checkpoint Inhibitor Therapy

7. Discussion of Novel Checkpoint Inhibitors and Combination Therapy

8. Dostarlimab in MSI-High Gastrointestinal Cancers- Latest Data, Expansion Cohorts, and Basket Trial Insights

9. Evolving Treatment Paradigms- Immunotherapy in Advanced Bladder Cancer

10. IL-2-Stimulating Agents from Early Drug Development

11. Innovations in Small Cell Lung Cancer- DLL3 Agents and Adjuvant Durvalumab

12. Intrathecal Immunotherapy- A Novel Path in Treating Leptomeningeal Disease no video

13. Mechanism of Action of Checkpoint Blockade PD1, PDL1, CTLA-4

14. Melanoma Subtypes are a Microcosm for Immune Checkpoint Blockade Efficacy Across Oncology-

15. Neurotoxicity in CAR T-Cell Therapy- Recognition and Management

16. Overview of Adverse Events in the Cell Therapy Patient- A Discussion of CRS, ICANS, and Prolonged Cytopenias

17. Q&A and Discussion – 01

18. Q&A and Discussion – 02

19. Q&A and Discussion – 03

20. Q&A and Discussion – 04

21. Q&A and Discussion

22. Targeting Multiple Myeloma with Bispecific Immune-Modulating Agents

23. The Role of T-Cell Therapy in Standard Care for Synovial Sarcoma

24. Understanding Chimeric Antigen Receptor (CAR) T-Cell Therapy